Department of Genetics. Institut Curie. PSL Research University, Paris, France.
Unit of Prevention and Genetic Epidemiology, UMR CNRS, 5558, Centre Léon Bérard, Lyon, France.
Eur J Med Genet. 2020 Dec;63(12):104078. doi: 10.1016/j.ejmg.2020.104078. Epub 2020 Oct 12.
MUTYH-associated polyposis (MAP) was first described in 2002. It is an autosomal recessive condition associated with germline pathogenic variants of both MUTYH alleles. In 2011, a group of French experts reviewed the available data on this syndrome and established recommendations concerning the indications and strategies for molecular analysis of the MUTYH gene in index cases and their relatives, as well as the clinical management of affected individuals under the auspices of the French Institut National du Cancer (INCa). Some of these recommendations have become obsolete as a result of recent progress, especially those concerning the molecular strategy for MUTYH testing, as this gene has recently been included in a consensus panel of 14 colorectal cancer predisposition genes, justifying revision of the previous report. We report here the revised version of this work, which successively considers the phenotype and tumor risks associated with this genotype, differential diagnoses, criteria and strategy for molecular genetic testing and recommendations for the management of affected individuals. We also discuss the phenotype and tumor risks associated with monoallelic pathogenic variants of MUTYH.
MUTYH 相关性息肉病(MAP)于 2002 年首次描述。它是一种常染色体隐性疾病,与 MUTYH 两个等位基因的种系致病性变异相关。2011 年,一组法国专家审查了该综合征的现有数据,并在法国国家癌症研究所(INCa)的主持下,就索引病例及其亲属的 MUTYH 基因分子分析的适应证和策略,以及受影响个体的临床管理提出了建议。由于最近的进展,其中一些建议已经过时,特别是关于 MUTYH 检测的分子策略,因为该基因最近被纳入了一个包含 14 个结直肠癌易感性基因的共识小组,这证明了之前报告的修订是合理的。我们在此报告这项工作的修订版本,它依次考虑了与这种基因型相关的表型和肿瘤风险、鉴别诊断、分子遗传学检测的标准和策略,以及受影响个体的管理建议。我们还讨论了 MUTYH 单等位基因致病性变异与表型和肿瘤风险的关系。